MedPath
HSA Approval

CO-ERBETAN FILM-COATED TABLET 300MG/12.5MG

SIN15178P

CO-ERBETAN FILM-COATED TABLET 300MG/12.5MG

CO-ERBETAN FILM-COATED TABLET 300MG/12.5MG

February 20, 2017

GOLDPLUS UNIVERSAL PTE LTD

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD
Licence HolderGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

C09DA04

irbesartan and diuretics

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

Macleods Pharmaceuticals Limited

Active Ingredients

Hydrochlorothiazide

12.50mg

Hydrochlorothiazide

Irbesartan

300.00mg

Irbesartan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CO-ERBETAN FILM-COATED TABLET 300MG/12.5MG - HSA Approval | MedPath